| Name | Title | Contact Details |
|---|
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
Cellnetix is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements
Radient Pharmaceuticals Corporation is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intracel Resources is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.